MX2017014084A - Formulaciones de deposito inyectables. - Google Patents

Formulaciones de deposito inyectables.

Info

Publication number
MX2017014084A
MX2017014084A MX2017014084A MX2017014084A MX2017014084A MX 2017014084 A MX2017014084 A MX 2017014084A MX 2017014084 A MX2017014084 A MX 2017014084A MX 2017014084 A MX2017014084 A MX 2017014084A MX 2017014084 A MX2017014084 A MX 2017014084A
Authority
MX
Mexico
Prior art keywords
injectable depot
depot formulations
formulations
compositions
treatment
Prior art date
Application number
MX2017014084A
Other languages
English (en)
Other versions
MX385405B (es
Inventor
Ashton Paul
Original Assignee
Psivida Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psivida Inc filed Critical Psivida Inc
Publication of MX2017014084A publication Critical patent/MX2017014084A/es
Publication of MX385405B publication Critical patent/MX385405B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Quinoline Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

Se describen composiciones y métodos relacionados con el uso de inhibidores de cinasa para el tratamiento de la degeneración macular y/o la oclusión de la vena retiniana.
MX2017014084A 2015-05-05 2016-05-05 Composición inyectable en el vítreo de un ojo que comprende un inhibidor de cinasa y el uso de la misma para tratar una enfermedad ocular. MX385405B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562157257P 2015-05-05 2015-05-05
PCT/US2016/030912 WO2016179357A1 (en) 2015-05-05 2016-05-05 Injectable depot formulations

Publications (2)

Publication Number Publication Date
MX2017014084A true MX2017014084A (es) 2018-06-20
MX385405B MX385405B (es) 2025-03-18

Family

ID=57218334

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014084A MX385405B (es) 2015-05-05 2016-05-05 Composición inyectable en el vítreo de un ojo que comprende un inhibidor de cinasa y el uso de la misma para tratar una enfermedad ocular.

Country Status (10)

Country Link
US (1) US20160324836A1 (es)
EP (1) EP3291812B1 (es)
JP (1) JP2018520093A (es)
CN (1) CN107530334A (es)
AU (1) AU2016258001B2 (es)
BR (1) BR112017023762A2 (es)
CA (1) CA2984637A1 (es)
MX (1) MX385405B (es)
RU (1) RU2017137763A (es)
WO (1) WO2016179357A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6847848B2 (ja) 2014-12-15 2021-03-24 ザ ジョーンズ ホプキンズ ユニバーシティＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ スニチニブ製剤、及び緑内障の治療におけるその使用方法
HK1257499A1 (zh) 2015-11-12 2019-10-25 Graybug Vision, Inc. 用於治疗的聚集性微粒
EP3600324A4 (en) 2017-03-23 2020-12-09 Graybug Vision, Inc. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISORDERS
AU2018265415A1 (en) 2017-05-10 2019-10-31 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
EP3982930A1 (en) * 2019-06-11 2022-04-20 SIFI S.p.A. Microemulsion compositions
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2156834A1 (en) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye
CN101890018B (zh) * 2009-05-22 2014-06-18 中国科学院化学研究所 一种酪氨酸蛋白激酶抑制剂及其制备方法
CN103764118A (zh) * 2011-06-28 2014-04-30 拜尔健康护理有限责任公司 含有索拉非尼的局部眼用药用组合物
HK1202333A1 (en) * 2011-11-11 2015-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
PE20142103A1 (es) * 2011-12-14 2015-01-11 Abbvie Inc Composiciones que contienen inhibidores de quinasas

Also Published As

Publication number Publication date
BR112017023762A2 (pt) 2018-07-31
RU2017137763A (ru) 2019-06-05
AU2016258001B2 (en) 2020-06-04
MX385405B (es) 2025-03-18
AU2016258001A1 (en) 2017-11-09
RU2017137763A3 (es) 2019-08-21
CN107530334A (zh) 2018-01-02
CA2984637A1 (en) 2016-11-10
JP2018520093A (ja) 2018-07-26
EP3291812A4 (en) 2019-01-09
EP3291812A1 (en) 2018-03-14
EP3291812B1 (en) 2021-09-01
WO2016179357A1 (en) 2016-11-10
US20160324836A1 (en) 2016-11-10

Similar Documents

Publication Publication Date Title
MX2017014084A (es) Formulaciones de deposito inyectables.
CO2017011535A2 (es) Composiciones de ácido obeticólico y métodos de uso
MX2018013983A (es) Inhibidores g12c de kras.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
DK3889145T3 (da) 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme
CL2018001652A1 (es) Composiciones y métodos para disminuir la expresión de tau
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
MX382033B (es) Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
MX387097B (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
MX2017011269A (es) Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos.
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
MX388752B (es) Composiciones novedosas, usos y métodos para hacerlas.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
MX395231B (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos.
MX395032B (es) Ciertos inhibidores de la proteína quinasa.
MX374385B (es) Apilimod para uso en el tratamiento de melanoma.
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
WO2016073771A3 (en) Pyrrolopyrimidine derivatives as mps1/ttk kinase inhibitors
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.
CO2018008249A2 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet